Senior staff writer, Features.
Pharmaceutical patents are used to extend monopolies, leading to high drug prices, and reduced access. Will the psychedelic industry follow suit?
A new study looked to the eyes for a potential test for aphantasia, or the inability to conjure up imagery in the mind.
Corporations are going to use IP law to profit from psychedelics. But creative strategies from other industries could help people push back against exclusionary ownership and keep drugs accessible.
Participants in a new study could correctly match a person to their heartbeat just by watching a video of their face, raising questions about how we sense what others are feeling.
The words “neurodiversity” and “neurodivergent” are being used widely, from workplace initiatives to social media. But what do they really signify?
Research on a surge of gamma wave activity at death has been cited as proof your life flashes before your eyes before you die; in truth, no one knows exactly what it means.
Before psychedelic therapy and services becomes widely available, there needs to be a better understanding of all the ways these experiences can go wrong.
The need for financial—and personal—disclosures is another growing pain for the nascent psychedelics industry.
The study of false—sober—insights teaches us to be wary of accepting every realization from psychedelic trips without critical thinking.